Europe Male Infertility Market 2023-2030

Europe Male Infertility Market 2023-2030

MARKET OUTLOOK

Triton Market Research’s report that the male infertility market in Europe will display a compound annual growth rate of 4.59% in revenue during 2023-2030. Germany, Italy, the United Kingdom, Spain, France, Poland, and the Rest of Europe are considered in the region.

In France, the increasing prevalence of lifestyle-oriented diseases, rising stress levels, and higher smoking rates contribute to higher rates of male infertility. According to Macrotrends, the current fertility rate in 2023 stands at 1.848 births per woman, marking a slight decrease of 0.05% from 2022. Further, the International Cancer Genome Consortium estimates that around 70,000 new prostate cancer cases are detected yearly, resulting in 8,700 deaths annually. Hence, these factors elevate the demand for male infertility testing across the nation.

The Italian market is estimated to expand due to key factors such as increasing male infertility cases and lifestyle-related changes, including diet, pollution, stress, and obesity. Stress, anxiety, and health issues are also significant factors impacting the male infertility market. Further, prostate cancer is on the rise, which is anticipated to generate opportunities for the male infertility market.

COMPETITIVE OUTLOOK

The eminent firms in the male infertility market include EMD Serono Inc, Bayer AG, Sanofi SA, Zydus Lifesciences Limited, and Endo International Plc.